Q2 FY2026 EarningsQ2 FY26 results significantly outperformed consensus, with revenue reaching $99.3M vs. $87.8M expected and a gross margin of 56.0% beating the 49.7% forecast. U.S. Amtagvi sales of ~$91M drove the 66% YoY growth, supported by record demand and expanding treatment centers. Management is now reviewing its FY26 revenue guidance of $350M-$370M for a potential upward revision, signaling strong momentum in the TIL therapy market.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Iovance Biotherapeautics(IOVA) the Revenue is 99.31 M (+65.65%), Beat estimate;the EBIT is -51.91 M (+54.38%), Beat estimate;the EPS is -0.11 (+66.67%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.10B65.65%
0.09B46.51%
+0.01B19.14%
EBITExceed expectations
-0.05B54.38%
-0.06B47.00%
+0.01B7.38%
EPSExceed expectations
-0.1166.67%
-0.134859.15%
+0.02487.52%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf